# BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
Canonical URL: https://biopharmsignal.com/news/BCRX/biocryst-announces-european-licensing-agreement-with-irish-affiliate-of-neopharmed-gentili-for-navenibart-in-hereditary-angioedema
Ticker: BCRX
Company: BioCryst Pharmaceuticals
Source: BioCryst Pharmaceuticals
Published: 2026-05-04 11:00 EST
Original Source URL: https://ir.biocryst.com
## Summary

— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe — — BioCryst to receive $70M upfront, up to $275M in future regulatory and sales milestone payments, and royalties on sales ranging from 18 to 30 percent — —

## Article Body
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe — — BioCryst to receive $70M upfront, up to $275M in future regulatory and sales milestone payments, and royalties on sales ranging from 18 to 30 percent — —
## Recent Company News
- 2026-05-27 11:00 EST — [BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting](https://biopharmsignal.com/news/BCRX/biocryst-to-present-new-hae-data-from-orladeyor-berotralstat-and-navenibart-at-the-2026-european-academy-of-allergy-and-clinical-immunology-annual-meeting) — Source: BioCryst Pharmaceuticals
- 2026-05-13 11:00 EST — [BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026](https://biopharmsignal.com/news/BCRX/biocryst-to-present-new-real-world-evidence-underscoring-the-ongoing-burden-of-pediatric-hereditary-angioedema-at-ispor-2026) — Source: BioCryst Pharmaceuticals
- 2026-05-06 11:00 EST — [BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/BCRX/biocryst-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: BioCryst Pharmaceuticals
- 2026-05-05 11:00 EST — [BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: BioCryst Pharmaceuticals
- 2026-05-04 11:00 EST — [BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema](https://biopharmsignal.com/news/BCRX/biocryst-announces-european-licensing-agreement-with-irish-affiliate-of-neopharmed-gentili-for-navenibart-in-hereditary-angioedema) — Source: BioCryst Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)